• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Pharmaceuticals

FDA accepts NDA for over-the-counter Narcan nasal spray from Emergent BioSolutions

December 14, 2022 By Sean Whooley

Emergent Biosolutions Narcan

Emergent BioSolutions (NYSE:EBS) recently announced that the FDA accepted for review its over-the-counter Narcan (naloxone HCI) nasal spray. The FDA last week accepted Emergent’s supplemental new drug application (sNDA) for the Narcan opioid overdose emergency treatment. It also granted the application priority review. If approved, it would represent the first 4 mg naloxone nasal spray […]

Filed Under: Business/Financial News, Drug-Device Combinations, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance Tagged With: Emergent BioSolutions, FDA

FDA accepts NDA for intranasal epinephrine from ARS Pharmaceuticals

December 8, 2022 By Sean Whooley

ARS pharmaceuticals neffy neurelis

ARS Pharmaceuticals announced today that the FDA accepted its new drug application (NDA) for neffy, its intranasal epinephrine. The offering covers the emergency treatment of severe type I allergic reactions in children and adults weighing 30 kg (66 pounds) or more. The company set an anticipated target action date of mid-2023 for its PDUFA (Prescription […]

Filed Under: Business/Financial News, Drug-Device Combinations, Food & Drug Administration (FDA), Pharmaceuticals Tagged With: arspharmaceuticals, Neurelis Inc.

Vaxxas raises $23M for needle-free drug delivery tech

December 5, 2022 By Sean Whooley

Vaxxas micropatch vaccine COVID-19

Vaxxas announced today that it completed a financing round that brings in $23 million (A$34 million) in new funds. Existing investors OneVentures and UniQuest led the round. New investors, including members of the Vaxxas board and management team, along with individual investors, participated. The company earmarked proceeds to advance its clinical programs, including its needle-free […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals Tagged With: Vaxxas

BD opens $38.6M medication management manufacturing plant in Mexico

December 2, 2022 By Sean Whooley

This is the logo of BD.

BD (NYSE:BDX) announced recently that it inaugurated a new $38.6 million manufacturing facility in Tijuana, Mexico. Government officials from Mexico and the state of Baja California joined in the opening of the medication management plant. BD plans for the facility to produce devices and technologies that improve medication safety within healthcare settings. According to a […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: BD

PharmaJet wins NIH grant to evaluate needle-free delivery of HPV immunization

November 29, 2022 By Sean Whooley

PharmaJet Tropis needle-free intradermal injection system

PharmaJet announced today that it received a grant worth $800,000-plus from the NIH to evaluate its needle-free injection system. Golden, Colorado-based PharmaJet picked up a Phase II grant from the NIH (National Institutes of Health). It allows the company to evaluate the immunogenicity of the intradermal administration of human papillomavirus virus (HPV) vaccine. The study […]

Filed Under: Business/Financial News, Clinical Trials, Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals, Preclinical Trials Tagged With: National Institutes of Health, PharmaJet

Bionaut Labs closes $43M Series B for robotic drug delivery tech

November 28, 2022 By Sean Whooley

Bionaut Labs robotic drug delivery

Robotic drug delivery technology developer Bionaut Labs announced today that it closed a Series B financing round worth $43.2 million. Los Angeles-based Bionaut Labs uses microscale robots to deliver drugs for treating central nervous system (CNS) diseases and disorders. Through magnetic propulsion, the company’s Bionauts can navigate the human body and deliver drugs locally. The […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Neurological, Oncology, Pharmaceuticals, Technology Tagged With: Bionaut Labs

Oramed inks deal to commercialize oral insulin in the Republic of Korea

November 14, 2022 By Sean Whooley

Oramed Logo

Oramed Pharmaceuticals (Nasdaq:ORMP) announced today that it entered into a distribution agreement for its oral insulin candidate in the Republic of Korea. The New York-based developer of oral drug delivery platforms entered into an exclusive commercial distribution agreement with Medicox. The agreement covers the distribution of ORMD-0801 in the Republic of Korea (formerly South Korea). […]

Filed Under: Business/Financial News, Diabetes, Distribution, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: oramedpharmaceuticals

Enable Injections to add hundreds of jobs in Ohio

October 31, 2022 By Sean Whooley

enfuse-enable-injections

Enable Injections announced today that it committed to increasing jobs and payroll in the Cincinnati, Ohio region. The company intends to add 257 jobs and nearly $20 million in payroll in Cincinnati by 2027. Ohio’s Tax Credit Authority Board approved the commitment today. It allows the company to benefit from Ohio’s Job Creation Tax Credit […]

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: Enable Injections

Rani Therapeutics launches RT-111 development program

October 26, 2022 By Sean Whooley

Rani Therapeutics

Robotic pill company Rani Therapeutics (Nasdaq:RANI) has begun developing RT-111, a RaniPill GO capsule containing a biosimilar of Johnson & Johnson’s (NYSE:JNJ) Stelara (ustekinumab). The company anticipates that RT-111 could potentially treat psoriatic arthritis, ulcerative colitis, Crohn’s disease and psoriasis. The FDA first approved Stelara in 2009 for psoriasis. Stelara is available in intravenous and […]

Filed Under: Business/Financial News, Drug-Device Combinations, Pharmaceuticals, Research & Development Tagged With: Johnson & Johnson, Rani Therapeutics

BD, Biocorp partner on connectivity for self-administered injectable drugs

October 18, 2022 By Sean Whooley

BD Biocorp

BD (NYSE:BDX) announced that it entered into an agreement with Biocorp with the aim to use connected technology with injectable drugs. The companies seek to track adherence for self-administered drug therapies, including biologics. They plan to integrate France-based Biocorp’s Injay technology with BD’s UltraSafe Plus passive needle guard. Biocorp designed Injay to capture and transmit […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: BD, biocorp

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 13
  • Page 14
  • Page 15
  • Page 16
  • Page 17
  • Interim pages omitted …
  • Page 210
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS